Russell Investments Group Ltd. Has $427,000 Position in Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA)

Russell Investments Group Ltd. lessened its holdings in Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) by 55.7% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 23,069 shares of the biotechnology company’s stock after selling 28,954 shares during the period. Russell Investments Group Ltd.’s holdings in Momenta Pharmaceuticals were worth $427,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in MNTA. Ameritas Investment Partners Inc. lifted its position in shares of Momenta Pharmaceuticals by 14.9% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 6,446 shares of the biotechnology company’s stock worth $109,000 after purchasing an additional 834 shares during the period. Pinebridge Investments L.P. lifted its position in shares of Momenta Pharmaceuticals by 4.3% in the 2nd quarter. Pinebridge Investments L.P. now owns 8,798 shares of the biotechnology company’s stock worth $149,000 after purchasing an additional 363 shares during the period. Profund Advisors LLC lifted its position in shares of Momenta Pharmaceuticals by 13.1% in the 2nd quarter. Profund Advisors LLC now owns 13,172 shares of the biotechnology company’s stock worth $223,000 after purchasing an additional 1,530 shares during the period. Citigroup Inc. lifted its position in shares of Momenta Pharmaceuticals by 263.2% in the 2nd quarter. Citigroup Inc. now owns 13,736 shares of the biotechnology company’s stock worth $232,000 after purchasing an additional 9,954 shares during the period. Finally, Piedmont Investment Advisors LLC purchased a new stake in shares of Momenta Pharmaceuticals in the 2nd quarter worth approximately $244,000. 93.40% of the stock is owned by hedge funds and other institutional investors.

Several equities research analysts have recently weighed in on the stock. Goldman Sachs Group assumed coverage on shares of Momenta Pharmaceuticals in a research report on Thursday, September 28th. They issued a “neutral” rating and a $18.00 price target for the company. Barclays reissued an “equal weight” rating and set a $16.00 target price (down previously from $17.00) on shares of Momenta Pharmaceuticals in a research report on Wednesday, October 4th. Zacks Investment Research raised shares of Momenta Pharmaceuticals from a “hold” rating to a “buy” rating and set a $20.00 target price for the company in a research report on Wednesday, October 4th. Stifel Nicolaus reissued a “hold” rating and set a $15.00 target price (down previously from $22.00) on shares of Momenta Pharmaceuticals in a research report on Wednesday, October 4th. Finally, BidaskClub raised shares of Momenta Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Tuesday. Two equities research analysts have rated the stock with a sell rating, nine have issued a hold rating and one has issued a buy rating to the company. The stock currently has an average rating of “Hold” and an average price target of $15.00.

In other news, Director Elizabeth Stoner sold 5,500 shares of the stock in a transaction on Wednesday, December 13th. The shares were sold at an average price of $13.10, for a total value of $72,050.00. Following the sale, the director now owns 13,240 shares in the company, valued at $173,444. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Craig A. Wheeler sold 35,666 shares of the stock in a transaction on Tuesday, January 2nd. The stock was sold at an average price of $14.11, for a total transaction of $503,247.26. The disclosure for this sale can be found here. Insiders sold 49,505 shares of company stock worth $685,923 in the last quarter. Company insiders own 4.40% of the company’s stock.

Momenta Pharmaceuticals, Inc. (NASDAQ MNTA) opened at $15.75 on Friday. Momenta Pharmaceuticals, Inc. has a 52 week low of $11.85 and a 52 week high of $19.90. The stock has a market cap of $1,200.00, a P/E ratio of -19.69 and a beta of 1.66.

Momenta Pharmaceuticals (NASDAQ:MNTA) last issued its quarterly earnings results on Wednesday, November 1st. The biotechnology company reported ($0.44) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.47) by $0.03. Momenta Pharmaceuticals had a negative net margin of 55.61% and a negative return on equity of 16.20%. The business had revenue of $24.09 million for the quarter, compared to analyst estimates of $29.58 million. During the same quarter in the prior year, the business posted ($0.26) EPS. Momenta Pharmaceuticals’s revenue for the quarter was down 17.3% compared to the same quarter last year. research analysts forecast that Momenta Pharmaceuticals, Inc. will post -1.16 earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: “Russell Investments Group Ltd. Has $427,000 Position in Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA)” was originally reported by Week Herald and is the property of of Week Herald. If you are accessing this piece on another website, it was illegally copied and republished in violation of international copyright & trademark laws. The original version of this piece can be accessed at https://weekherald.com/2018/01/13/russell-investments-group-ltd-sells-28954-shares-of-momenta-pharmaceuticals-inc-mnta.html.

Momenta Pharmaceuticals Profile

Momenta Pharmaceuticals, Inc is a biotechnology company. The Company is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. The Company has developed generic version of LOVENOX (enoxaparin sodium injection) and COPAXONE (glatiramer acetate injection).

Institutional Ownership by Quarter for Momenta Pharmaceuticals (NASDAQ:MNTA)

Receive News & Ratings for Momenta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momenta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply